Business
Nottingham Trent University Cancer Protein Study
Nottingham Trent University Cancer Protein Study.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 5685V Scancell Holdings Plc 16 December 2013 \n \n\n16 December 2013\n \n \nScancell Holdings Plc\n \nImmunobody® Technology Used in Prostate Cancer Protein Discovery\n \nScancell Holdings plc ('Scancell' or the 'Company'), the developer of novel immunotherapies for the treatment of cancer, notes Nottingham Trent University's announcement that using Scancell's Immunobody® technology, they have unlocked a protein that could pave the way for future prostate cancer vaccinations. The full text of Nottingham Trent University's announcement follows:\n \n \nscientists unlock prostate cancer protein in move which could lead to improved cancer vaccines\n \nUK scientists have identified how a specific region of a prostate-related protein can be used to trigger the body's immune response against prostate cancer. The study by scientists at Nottingham Trent University - and published in the European Journal of Immunology - could pave the way for new and improved vaccines for prostate cancer.\n \nThe work focused on the prostatic acid phosphatase (PAP) protein, which is present in more than 90% of prostate tumours. Scientists were able to develop a new prostate cancer vaccination strategy utilising a portion, or 'epitope' of this PAP protein - PAP 114 - which was capable of preventing and reducing tumour growth in pre-clinical trials.\n \nThe team believes the study could lead to the development of new vaccines which are able to generate a more specific, more efficient, faster and longer-lasting protective immune response against prostate cancer. \n \nIt might also mean that vaccines could be developed at a lower cost than currently, and with fewer potential side effects, say the scientists, who are based in the university's John van Geest Cancer Research Centre. \n \nProstate cancer is the most common cancer in men in the UK - each year more than 10,000 men will die as a result of prostate cancer and more than 40,000 will be diagnosed with the disease. Cases are rising among men over 50 and the average age for men to be diagnosed is between 70 and 74.\n \nAlthough cancer vaccines can be formulated in a number of different ways, the approach devised by the scientists for this PAP vaccine would involve a series of injections. \n \nDr Stephanie ...